Sat, Aug 30, 2014, 7:17 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Heartware International Inc. Message Board

  • cjgaddy cjgaddy Nov 21, 2012 7:41 AM Flag

    11-21-12 Wells Fargo Downgrades Heartware Post FDA Approval

    11-21-12: ”Wells Fargo Downgrades Heartware (HTWR) to Market Perform Post FDA Approval”
    Wells Fargo downgraded Heartware Int'l (NASDAQ: HTWR) from Outperform to Market Perform and lowers its valuation range from $97-99 to $88-89 after the FDA approved HVAD pump for use in bridge-to-transplant.
    The firm cited:
    (1) We think the Street has not modeled the HTWR launch precisely enough and, as a result, we are below 2013 consensus revenue already and expect consensus will come down
    (2) The new stroke data may dampen the HVAD roll-out in the U.S.
    (3) The risk to the HTWR ENDURANCE DT trial failing, or being positive, but having a problematically high stroke rate, is now increased given the interim data in the IFU, in our view."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
81.10+0.72(+0.90%)Aug 29 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.